Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05880537

Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry

Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Infirmary Heath, Mobile, Alabama, United States

Loading trial locations.

About this study

The clinical objective of this prospective, observational, post market registry study, CR-21-005, is to assess the safety and efficacy of a decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery, LifeNet Health, Virginia Beach, VA) in the creation of vascular access for hemodialysis in patients with ESRD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be male or female, ≥18 years of age at the time of graft placement
  • Have a diagnosis of ESRD or renal dysfunction requiring hemodialysis
  • Subject requires dialysis access to start or maintain dialysis treatment and placement of an AV access graft is a viable access option.
  • Have the ability themselves, or through their legal guardian, to understand the requirements of the study, to provide written informed consent/assent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and to agree to abide by the study restrictions and return to the site for the required assessments
  • Have provided written authorization for use and disclosure of protected health information

Exclusion criteria

  • Be participating in a study of another investigational drug or device
  • Have a known sensitivity to any of the processing reagents utilized in the manufacture of this product such as antibiotics (Lincomycin, Polymyxin B, Ciprofloxacin, Meropenum, Gentamicin, or Vancomycin) and processing reagents (N-lauroyl sarcosine, Denarase and glycerol/glycerin)
  • Have a history or evidence of severe cardiac disease, myocardial infarction within 6 months, ventricular arrhythmias, or unstable angina requiring continuing treatment
  • Have a history or evidence of severe peripheral vascular disease in the upper extremities
  • Have the inability or be unable or unwilling to follow the study visit schedule
  • Have the presence of any condition that, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated

Treatment and study plan

Nexeon Arterial Venous Allograft

Other

Nexeon AVX allograft for hemodialysis access in end stage renal disease

Primary outcomes

  1. UltraSound evaluation of allograft functional patency.

    Time frame: 24 months

    Ultrasound proof of vessel patency and blood flow

Secondary outcomes

  1. Secondary Endpoint:

    Time frame: 24 months

    Evaluating the emergent adverse events as it pertains to the hemodialysis access anatomical site

Study contacts

Contact information is provided by the study sponsor or research team.

Kimberly Dorsch

CONTACT

[email protected]

757-609-4378

Monique Alston-Epps

CONTACT

[email protected]

757-713-4657

Sponsors and collaborators

Lead sponsor

LifeNet Health

Industry

Registry information

Official study title

Safety, Efficacy, & Use of Decellularized Femoral Artery Allograft for Arteriovenous Access for Hemodialysis: A Multi-center Prospective Registry Study

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
May 30, 2023
Registry last updated
Apr 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.